Literature DB >> 19693480

[Therapy of local prostate carcinoma. Questions answered by outcome research].

D Schnell1, H Schön, L Weissbach.   

Abstract

More and more localized prostate cancers with only a low risk for progression are diagnosed. In most cases the treatment consists of invasive procedures which may be accompanied by certain side effects. Ongoing randomized studies which are comparing irradiation and surgery with defensive strategies like Active Surveillance will not give results in the foreseeable future. In this situation it could be helpful to take data from health care research studies like HAROW. Neither the physicians nor the patients participating are selected. As a non-interventional study HAROW provides a data collecting in invasive therapies and in defensive strategies. Under everyday conditions data on cancer history, quality of life, patients' satisfaction and economics are collected. Since Active Surveillance (AS) is still a largely uncommon strategy we present criteria for enrollment, ongoing and termination. In international guidelines AS is assessed to be on a par with invasive procedures or even as the preferred treatment option.

Entities:  

Mesh:

Year:  2009        PMID: 19693480     DOI: 10.1007/s00120-009-2082-5

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  7 in total

1.  Types of study in medical research: part 3 of a series on evaluation of scientific publications.

Authors:  Bernd Röhrig; Jean-Baptist du Prel; Daniel Wachtlin; Maria Blettner
Journal:  Dtsch Arztebl Int       Date:  2009-04-10       Impact factor: 5.594

Review 2.  Active surveillance or active treatment in localized prostate cancer?

Authors:  Lothar Weissbach; Jens Altwein
Journal:  Dtsch Arztebl Int       Date:  2009-05-29       Impact factor: 5.594

3.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Authors:  Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

4.  A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy.

Authors:  Derek B Chism; Alexandra L Hanlon; Eric M Horwitz; Steven J Feigenberg; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

5.  Trials of prostate-cancer screening are not worthwhile.

Authors:  Hans-Hermann Dubben
Journal:  Lancet Oncol       Date:  2009-03       Impact factor: 41.316

6.  Population-based study of long-term survival in patients with clinically localised prostate cancer.

Authors:  G L Lu-Yao; S L Yao
Journal:  Lancet       Date:  1997-03-29       Impact factor: 79.321

7.  A challenge to contemporary management of prostate cancer.

Authors:  Peter C Albertsen
Journal:  Nat Clin Pract Urol       Date:  2008-12-09
  7 in total
  3 in total

1.  [Patient centeredness and decision-making in localised prostate cancer: possible fields of health services research in urology].

Authors:  J Huber; A Ihrig; C G Huber; B Hadaschik; S Pahernik; M Hohenfellner
Journal:  Urologe A       Date:  2011-06       Impact factor: 0.639

2.  The Treatment of Localized Prostate Cancer in Everyday Practice in Germany.

Authors:  Jan Herden; Lena Ansmann; Nicole Ernstmann; Dietrich Schnell; Lotharh Weißbac
Journal:  Dtsch Arztebl Int       Date:  2016-05-13       Impact factor: 5.594

3.  [The HAROW study: an example of outcomes research: a prospective, non-interventional study comparing treatment options in localized prostate cancer].

Authors:  J Herden; N Ernstmann; D Schnell; L Weißbach
Journal:  Urologe A       Date:  2014-12       Impact factor: 0.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.